Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This scoping review identifies various pharmacological agents and five key mechanistic strategies being studied in vivo to mitigate multi-organ toxicity caused by cytarabine, with apraglutide and N-acetylcysteine highlighted as promising candidates for clinical application.

This narrative review explores the strong association between various chronic inflammatory skin diseases and metabolic syndrome, emphasizing shared inflammatory pathways and chemokine involvement, though the precise molecular connections remain partially understood.

This review explores the role of FGF signaling in hair follicle development and highlights its potential as a new therapeutic target for hair loss, which could surpass existing treatments in terms of efficacy and safety.

This study demonstrated that Periplaneta americana extract significantly promoted hair regeneration in depilated mice by enhancing superoxide dismutase activity, upregulating vascular endothelial growth factor, modulating the FOXO/PI3K/AKT pathway, and restoring skin microbiome balance, suggesting its potential as a novel therapeutic candidate for alopecia.

This study found that CXCL12 inhibits hair growth via the CXCR4/STAT signaling pathway, suggesting that targeting this pathway could be a promising approach for promoting hair growth.

This study demonstrated that a microarray patch can deliver antibodies in a controlled and prolonged manner, maintaining their functionality after manufacturing and heat exposure, with successful pharmacokinetic proof-of-concept in rats.

This study found that the CYP3A4 rs4646437 genotype was significantly associated with ALT elevation in Japanese patients undergoing asunaprevir plus daclatasvir therapy for chronic HCV infection, suggesting genotyping may help in monitoring patients safely.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

In laboratory tests and mouse models, this study found that the novel IPC analog SIG-1451 may offer potent anti-inflammatory effects for treating allergic skin inflammation, potentially outperforming some current therapies in specific inflammatory phases.

This article reviews approved treatments for androgenetic alopecia and reports no new research findings, highlighting the need for further studies.

In this case study, treatment with the selective JAK1 inhibitor upadacitinib significantly improved symptoms in a patient with refractory alopecia areata, vitiligo, ankylosing spondylitis, and allergic asthma-nasal syndrome, though a transient liver function abnormality was noted.

This study found that astilbin downregulates effector CD4+ T cell activities through the CYP1B1/ROS/PPARγ pathway, suggesting its potential use in treating inflammation.

This case series found that patients with the NUDT15 415C>T variant experienced severe azathioprine toxicity, suggesting genotype-based dosing could reduce adverse effects.

This study found that a 50% ethanolic extract of Adiantum capillus had significant analgesic and anti-inflammatory effects in animals, particularly at the highest tested dose of 300 mg/kg.

In this study, researchers using network pharmacology and molecular docking methods found that compounds from Avicennia Marina could inhibit hepatitis C virus infection by targeting key proteins such as AKT1 and TNF-α, showing potential for anti-HCV treatments.

In this case report, two female patients with refractory systemic lupus erythematosus showed significant improvement after treatment with the JAK inhibitor upadacitinib, indicating potential as a promising option for difficult cases, although further research is needed to confirm its broader safety and efficacy.

In this report, a 25-year-old female patient with anti-MDA5 antibody-positive dermatomyositis and alopecia areata achieved complete remission of hair loss after treatment with baricitinib.

In this case report, a woman with ulcerative colitis experienced clinical deterioration during upadacitinib therapy, which improved after discontinuation, strongly suggesting drug hypersensitivity to the Janus kinase inhibitor as a potential cause for her symptoms.

This study developed BroadAMP-GPT, a computational-experimental framework, to discover new antimicrobial peptides, identifying candidates effective against multidrug-resistant pathogens. Notably, AMP_S13 showed strong stability, low toxicity, and efficacy in infection models, highlighting the platform's potential in combating antimicrobial resistance.

This study demonstrated that adenosine triphosphate may prevent vandetanib-induced skin toxicity in rats, suggesting potential for further research in other animal models and humans.

This study found that engineered high-affinity soluble CD200R agonists, including ARQ-234, showed superior efficacy in reducing immune responses in various preclinical models of inflammatory conditions, suggesting potential as a therapeutic for atopic dermatitis and other related diseases.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

This study developed dissolving microneedles incorporating a new AR degrader for treating androgenetic alopecia, showing that a single application leads to superior hair regeneration compared to daily minoxidil, without systemic toxicity or androgen-related issues.

OR101 may effectively treat atopic dermatitis and similar skin conditions.

In this study involving children with alopecia areata, researchers found that adding narrowband UVB 311 nm therapy to standard treatment significantly improved hair regrowth in those with coexisting atopic dermatitis compared to those without the condition.

This study reports a case where a patient with rheumatoid arthritis and alopecia areata saw significant improvement in both conditions after switching to daily upadacitinib treatment, specifically achieving complete hair regrowth within six months.

In this case report, a 28-year-old male with severe atopic dermatitis, prurigo nodularis-like lesions, and alopecia areata showed rapid improvements in skin and hair following treatment with the JAK1 inhibitor, ivarmacitinib, suggesting its potential benefit for complex AD phenotypes with immune-mediated hair loss.

This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.

This study found that using copper-doped mesoporous silica nanoparticles to deliver IL-1Ra and copper ions effectively reduced arterial stenosis, plaque burden, and macrophage infiltration in atherosclerosis, by promoting macrophage apoptosis and providing anti-inflammatory effects.

This study found that the JAK1 inhibitors baricitinib and abrocitinib significantly reduced mechanical alloknesis in a murine model of atopic dermatitis, whereas the JAK2 inhibitor AZ960 had no effect.